Carmine Therapeutics

Executive Summary

Carmine Therapeutics is a preclinical-stage biotechnology company pioneering next-generation non-viral gene therapies based on red blood cell extracellular vesicles (RBCEVs) through its proprietary REGENT platform. Founded in 2020 and headquartered in Cambridge, USA, the company addresses critical limitations of viral vectors—such as immunogenicity, limited payload capacity, and manufacturing complexity—by leveraging the natural biocompatibility, scalability, and modularity of RBCEVs. Carmine focuses on oncology, rare genetic diseases, and hematology, aiming to develop disease-modifying treatments that can be repeatedly dosed without triggering adverse immune responses. The REGENT platform enables the encapsulation of various therapeutic payloads, including mRNA, siRNA, and proteins, positioning the company to target a broad range of indications. As a private entity with an estimated 10-50 employees, Carmine is currently advancing its lead programs through preclinical development. The company's transformative approach has the potential to revolutionize gene therapy by providing a safer, more versatile delivery system. While specific financial details and pipeline timelines remain undisclosed, Carmine's innovative technology and experienced team in the Cambridge biotech hub position it favorably within the gene therapy landscape. The company's next milestones are likely to include regulatory filings, preclinical data readouts, and strategic partnerships that could validate its platform and accelerate clinical translation.

Upcoming Catalysts (preview)

• Q3 2027IND submission for lead RBCEV gene therapy program60% success
• Q1 2027Presentation of preclinical proof-of-concept data at major conference80% success
• Q4 2026Announcement of strategic partnership or licensing deal45% success